Latest news with #Danaher
National Post
15 hours ago
- Business
- National Post
SCIEX Sets a New Standard in Accurate Mass Quantitation With the ZenoTOF 8600 System and New Software Collaborations
Article content MARLBOROUGH, Mass. — At ASMS 2025, SCIEX, a global leader in life science analytical technologies and operating company of Danaher Corporation (NYSE: DHR), launches the ZenoTOF 8600 system, setting a new standard in accurate mass quantitation. The system is competitive in identification, superior in quantitation, and enhances structural understanding so scientists can now confidently quantify thousands of species from complex samples in short acquisition times. Article content Article content The ZenoTOF 8600 system brings sensitive quantitation and decades of SCIEX leadership in triple quad innovation to the ZenoTOF portfolio. Innovations include: Article content The OptiFlow Pro source, DJet ion guide, and QJet ion guide – Enables the system to generate and transmit more ions. When combined with the Zeno trap, this facilitates 10x improvement in sensitivity, compared to the ZenoTOF 7600+ system. Mass Guard technology, introduced last year on the SCIEX 7500+ system – Protects the system from contamination and increases uptime. New optical detector – Allows the system to operate effectively at higher ion currents. ZT Scan DIA 2.0 – Covers a larger mass range so scientists can now quantify what was previously a struggle to identify – across all omics disciplines. ZT Scan DIA 2.0 is a transformation of the most comprehensive SCIEX DIA approach. Article content 'The ZenoTOF 8600 system gives you the resolution and speed you need, but the sensitivity allows us to do everything on one box. We are not just seeing more things, we are identifying them, and at times 30-40% more. And because of ZT Scan DIA 2.0, there is this additional treasure of information that has increased our capacity to discover new things, which we were not anticipating. It's the first time I've been able to do nominal mass resolution on the precursor, which finally allows us to do SWATH type of analysis on lipids or complex natural products,' said Dr. Nicola Zamboni, Ph.D., Principal investigator and adjunct professor at the Institute of Molecular Systems Biology of ETH Zurich. 'As a result, these abilities enhance our capacity in discovery biology. They deepen our understanding of mechanisms. They help us find things that matter.' Article content To match the data processing needs of the ZenoTOF 8600 system, the new SCIEX OS software version 4.0 enhances operability with speed and automation. Automated workflow improvements and progressive software functionalities establish the benchmark for efficiency, accuracy, and precision. Article content This builds on the SCIEX OS ecosystem, to seamlessly connect innovations in hardware and software processing. A new software collaboration this year includes that with MS-Dial, an open-source software platform designed for untargeted metabolomics and lipidomics analysis. This collaboration enhances the identification and quantification of small molecules through advanced spectral deconvolution and library matching. The latest version of MS-Dial now supports SCIEX raw data across multiple scan modes and is well-suited for ZT Scan DIA, ensuring greater accuracy and efficiency in data analysis. Article content In addition, SCIEX and Bioinformatics Solutions Inc (BSI) continue to drive innovation in mass spectrometry-based proteomics solutions. The latest release of PEAKS Studio 13 translates data from ZT Scan DIA, SWATH DIA, and DDA to deliver expansive peptide identification, reliable protein inference, and novel peptides, as well as deep insight into the PTM and sequence variant expression within biological studies. This version also brings processing improvements for ZT Scan DIA, optimizing CV% and processing speed to ensure greater accuracy and efficiency in proteomics workflows. Article content 'This year's launches will enable us to see exciting impact across OMICS research. We are motivated by what our customers tell us, that they can foresee real-world outcomes as a result of the new data generated and the insights interpreted,' Jose Castro-Perez Ph.D., Vice president, product management at SCIEX. Article content About SCIEX Article content SCIEX empowers our customers to solve the most impactful analytical challenges in quantitation and characterization. With groundbreaking innovation and outstanding reliability and support, SCIEX has been at the forefront of the field for over 50 years. Article content Since the launch of the first-ever commercially successful triple quadrupole in 1981, we continue to develop technologies and solutions that influence life-changing research and outcomes. That's why thousands of life science experts around the world choose SCIEX to get the answers they can trust. Article content Advances in human wellness depend on the power of precise science. Article content SCIEX is proud to be part of Danaher. Article content Danaher's science and technology leadership puts SCIEX solutions at the forefront of the industry, so they can reach more people. Being part of Danaher means we can offer unparalleled breadth and depth of expertise and solutions to our customers. Together with Danaher's other businesses across Biotechnology, Diagnostics and Life Sciences, we unlock the transformative potential of cutting-edge science and technology to improve billions of lives every day. Article content The SCIEX clinical diagnostic portfolio is for in vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to All other products are For Research Use Only. Not for use in Diagnostic Procedures. Article content Trademarks and/or registered trademarks mentioned herein, including associated logos, are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries (see Article content Article content Article content Article content Article content Article content
National Post
15 hours ago
- Business
- National Post
Software Launches for SCIEX OS Ecosystem to Help Scientists Accelerate Discoveries and Streamline Lab Operations
Article content MARLBOROUGH, Mass. — SCIEX, a global leader in life science analytical technologies and operating company of Danaher Corporation (NYSE: DHR), announces three software ecosystem enhancements at ASMS. These developments will present new ways to acquire data, new standards for performance, and new practices to extract elevated insights, all supporting the theme that 'all science is data science now.' Article content This new Microsoft Windows 11 compatible release drives operability enhancements with speed and automation to improve customers' time to results. SCIEX OS 4.0 delivers advanced hardware support for the latest SCIEX innovations, including today's newly launched ZenoTOF 8600 system. In addition, automated workflow improvements and progressive software functionalities establish the benchmark for efficiency, accuracy, and precision. Article content The intuitive interface empowers operators to seamlessly integrate both new and existing workflows into SCIEX OS. This enables faster deployment and improves operational readiness when compared to previous SCIEX software systems. Administrative features within SCIEX OS 4.0 boosts security and compliance to the ecosystem so labs can produce data with the highest integrity and traceability. Article content AI Quantitation software ushers in a new era of artificial intelligence driven data processing automation. Article content AI Quantitation software is a focused solution that eliminates data process operator bias and accelerates actionable decision-making across the absorption, distribution, metabolism, and excretion (ADME) workflows. With the power of artificial intelligence, AI Quantitation software automatically predicts the most suitable fragments for MRM analysis of new compounds or analytes and eliminates the need for time-consuming compound standard infusions and manual fragment optimization. Article content The impact of AI Quantitation software reflects SCIEX and Mass Analytica's continued commitment towards drug discovery laboratories with practical, efficient tools. By integrating AI-driven automation into established workflows, this solution helps reduce manual workload, improve consistency, and support faster decision-making. Scientists can now focus more on research and less on routine data processing. Article content To improve accessibility, SCIEX supports the vibrant open-source software community with SCIEX MS Data Converter 2.0. Article content SCIEX strives to offer integrated SCIEX OS data processing so customers can unlock the full potential of their data, whether using open-source tools or their own data processing capabilities. Knowing the rapid innovation of the scientific community, SCIEX seeks to improve the usability, flexibility, and availability of our data to the entire community. SCIEX MS Data Converter 2.0 keeps pace with the latest software languages and ensures the highest quality of collaboration and service we strive for at SCIEX. Article content 'With these updates, we want to empower customers to take the next step in their LC-MS journey. We know software is a critical component of success for scientists, and the SCIEX OS ecosystem continues to prove its ability to provide the insights needed to make impactful discoveries and decisions,' said Chris Lock Ph.D., Vice president of global research and development at SCIEX. 'Our reoccurring theme this year is 'prove it.' The proof is in the data, and we invite you to come explore it with us.' Article content SCIEX empowers our customers to solve the most impactful analytical challenges in quantitation and characterization. With groundbreaking innovation and outstanding reliability and support, SCIEX has been at the forefront of the field for over 50 years. Article content Since the launch of the first-ever commercially successful triple quadrupole in 1981, we continue to develop technologies and solutions that influence life-changing research and outcomes. That's why thousands of life science experts around the world choose SCIEX to get the answers they can trust. Article content Advances in human wellness depend on the power of precise science. Article content SCIEX is proud to be part of Danaher. Article content Danaher's science and technology leadership puts SCIEX solutions at the forefront of the industry, so they can reach more people. Being part of Danaher means we can offer unparalleled breadth and depth of expertise and solutions to our customers. Together with Danaher's other businesses across Biotechnology, Diagnostics and Life Sciences, we unlock the transformative potential of cutting-edge science and technology to improve billions of lives every day. Article content The SCIEX clinical diagnostic portfolio is for in vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to All other products are For Research Use Only. Not for use in Diagnostic Procedures. Article content Trademarks and/or registered trademarks mentioned herein, including associated logos, are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries (see Article content Article content Article content Article content
National Post
15 hours ago
- Business
- National Post
SCIEX and Evosep expand access to standardized proteomics for Pharma and Biotech with new reseller agreement
Article content MARLBOROUGH, Mass. — SCIEX, a global leader in life science analytical technologies and operating company of Danaher Corporation (NYSE: DHR), and Evosep Biosystems, a global leader in proteomics solutions, enter a reseller agreement to co-sell SCIEX mass spectrometry systems with the newly announced Evosep Eno, for standardized high-throughput proteomics. Article content Article content The reseller agreement empowers researchers to implement standardized proteomics workflows, delivering a robust LC-MS solution designed to meet the evolving demands of pharmaceutical and biotech companies. With Evosep Eno, researchers gain exceptional throughput, sensitivity, and reproducibility. When combined with SCIEX mass spectrometers—engineered for speed and sensitivity in both quantitative and qualitative analyses—this collaboration ensures access to cutting-edge technology tailored to today's analytical challenges. Article content The latest research from SCIEX and Evosep, shows that the Evosep Eno provides an >5-fold increase of peptide precursor identifications and an >3-fold increase of protein group identifications, at 500 SPD, when coupled to the new ZenoTOF 8600 system. This enables a greater depth of proteome coverage for large-scale cohort, high-throughput analysis. Article content 'For the application of proteomics in translational medicine, this extended collaboration between SCIEX and Evosep will further adoption of standardized solutions and make the technology more accessible—even to those new to proteomics,' said Morten Bern, CEO of Evosep. 'Together, we have an exciting opportunity to make a meaningful impact through LC-MS–based proteomics by combining our strengths to deliver solutions that ultimately enhance patient care and improve quality of life.' Article content 'Our collaboration with Evosep over the years has allowed us to continue to advance and standardize high throughput proteomics workflows. It is exciting to see the exceptional performance for the quantitative identification of peptides and proteins in complex samples. We are committed to providing the best solution for our customers,' said Jose Castro-Perez Ph.D., Vice president of product management at SCIEX. Article content This agreement allows users to access SCIEX mass spectrometry systems and the Evosep Eno via a single product catalogue issued by SCIEX. This option is available to customers located in the USA, Canada, Germany, France, Italy, Switzerland, Austria, Spain, Portugal, Sweden, Norway, Denmark, Finland, Belgium, Netherlands, Latvia, Lithuania, Estonia, and Luxembourg. Both vendors commit to deliver coordinated service and leading analytical performance. SCIEX will support the full customer relationship and Evosep will provide direct UHPLC service and support. Article content SCIEX empowers our customers to solve the most impactful analytical challenges in quantitation and characterization. With groundbreaking innovation and outstanding reliability and support, SCIEX has been at the forefront of the field for over 50 years. Article content Since the launch of the first-ever commercially successful triple quadrupole in 1981, we continue to develop technologies and solutions that influence life-changing research and outcomes. That's why thousands of life science experts around the world choose SCIEX to get the answers they can trust. Article content Advances in human wellness depend on the power of precise science. Article content SCIEX is proud to be part of Danaher. Article content Danaher's science and technology leadership puts SCIEX solutions at the forefront of the industry, so they can reach more people. Being part of Danaher means we can offer unparalleled breadth and depth of expertise and solutions to our customers. Together with Danaher's other businesses across Biotechnology, Diagnostics and Life Sciences, we unlock the transformative potential of cutting-edge science and technology to improve billions of lives every day. Article content The SCIEX clinical diagnostic portfolio is for in vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to All other products are For Research Use Only. Not for use in Diagnostic Procedures. Article content Trademarks and/or registered trademarks mentioned herein, including associated logos, are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries (see Article content Article content Article content Article content
Associated Press
15 hours ago
- Health
- Associated Press
SCIEX Sets a New Standard in Accurate Mass Quantitation With the ZenoTOF 8600 System and New Software Collaborations
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Jun 2, 2025-- At ASMS 2025, SCIEX, a global leader in life science analytical technologies and operating company of Danaher Corporation (NYSE: DHR), launches the ZenoTOF 8600 system, setting a new standard in accurate mass quantitation. The system is competitive in identification, superior in quantitation, and enhances structural understanding so scientists can now confidently quantify thousands of species from complex samples in short acquisition times. This press release features multimedia. View the full release here: SCIEX launches the ZenoTOF 8600 system. The ZenoTOF 8600 system brings sensitive quantitation and decades of SCIEX leadership in triple quad innovation to the ZenoTOF portfolio. Innovations include: 'The ZenoTOF 8600 system gives you the resolution and speed you need, but the sensitivity allows us to do everything on one box. We are not just seeing more things, we are identifying them, and at times 30-40% more. And because of ZT Scan DIA 2.0, there is this additional treasure of information that has increased our capacity to discover new things, which we were not anticipating. It's the first time I've been able to do nominal mass resolution on the precursor, which finally allows us to do SWATH type of analysis on lipids or complex natural products,' said Dr. Nicola Zamboni, Ph.D., Principal investigator and adjunct professor at the Institute of Molecular Systems Biology of ETH Zurich. 'As a result, these abilities enhance our capacity in discovery biology. They deepen our understanding of mechanisms. They help us find things that matter.' To match the data processing needs of the ZenoTOF 8600 system, the new SCIEX OS software version 4.0 enhances operability with speed and automation. Automated workflow improvements and progressive software functionalities establish the benchmark for efficiency, accuracy, and precision. This builds on the SCIEX OS ecosystem, to seamlessly connect innovations in hardware and software processing. A new software collaboration this year includes that with MS-Dial, an open-source software platform designed for untargeted metabolomics and lipidomics analysis. This collaboration enhances the identification and quantification of small molecules through advanced spectral deconvolution and library matching. The latest version of MS-Dial now supports SCIEX raw data across multiple scan modes and is well-suited for ZT Scan DIA, ensuring greater accuracy and efficiency in data analysis. In addition, SCIEX and Bioinformatics Solutions Inc (BSI) continue to drive innovation in mass spectrometry-based proteomics solutions. The latest release of PEAKS Studio 13 translates data from ZT Scan DIA, SWATH DIA, and DDA to deliver expansive peptide identification, reliable protein inference, and novel peptides, as well as deep insight into the PTM and sequence variant expression within biological studies. This version also brings processing improvements for ZT Scan DIA, optimizing CV% and processing speed to ensure greater accuracy and efficiency in proteomics workflows. 'This year's launches will enable us to see exciting impact across OMICS research. We are motivated by what our customers tell us, that they can foresee real-world outcomes as a result of the new data generated and the insights interpreted,' Jose Castro-Perez Ph.D., Vice president, product management at SCIEX. To learn more about the ZenoTOF 8600 system, visit About SCIEX SCIEX empowers our customers to solve the most impactful analytical challenges in quantitation and characterization. With groundbreaking innovation and outstanding reliability and support, SCIEX has been at the forefront of the field for over 50 years. Since the launch of the first-ever commercially successful triple quadrupole in 1981, we continue to develop technologies and solutions that influence life-changing research and outcomes. That's why thousands of life science experts around the world choose SCIEX to get the answers they can trust. Advances in human wellness depend on the power of precise science. For more information, visit Connect with us on LinkedIn, Facebook, X (Twitter) and Instagram. SCIEX is proud to be part of Danaher. Danaher's science and technology leadership puts SCIEX solutions at the forefront of the industry, so they can reach more people. Being part of Danaher means we can offer unparalleled breadth and depth of expertise and solutions to our customers. Together with Danaher's other businesses across Biotechnology, Diagnostics and Life Sciences, we unlock the transformative potential of cutting-edge science and technology to improve billions of lives every day. The SCIEX clinical diagnostic portfolio is for in vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to All other products are For Research Use Only. Not for use in Diagnostic Procedures. Trademarks and/or registered trademarks mentioned herein, including associated logos, are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries (see ). © 2025 DH Tech. Dev. Pte. Ltd. MKT-35293-A. View source version on CONTACT: Lulu VanZandt Senior manager, brand, public relations and social media [email protected] M: +1 (508) 782-9484 KEYWORD: MASSACHUSETTS UNITED STATES UNITED KINGDOM NORTH AMERICA LATIN AMERICA ASIA PACIFIC EUROPE INDUSTRY KEYWORD: OTHER HEALTH SOFTWARE RESEARCH GENERAL HEALTH HARDWARE APPS/APPLICATIONS TECHNOLOGY HEALTH TECHNOLOGY SCIENCE BIOTECHNOLOGY OTHER TECHNOLOGY HEALTH SOURCE: SCIEX Copyright Business Wire 2025. PUB: 06/02/2025 07:00 AM/DISC: 06/02/2025 06:58 AM
Yahoo
16 hours ago
- Business
- Yahoo
Q1 Earnings Highlights: Thermo Fisher (NYSE:TMO) Vs The Rest Of The Research Tools & Consumables Stocks
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the research tools & consumables stocks, including Thermo Fisher (NYSE:TMO) and its peers. The life sciences subsector specializing in research tools and consumables enables scientific discoveries across academia, biotechnology, and pharmaceuticals. These firms supply a wide range of essential laboratory products, ensuring a recurring revenue stream through repeat purchases and replenishment. Their business models benefit from strong customer loyalty, a diversified product portfolio, and exposure to both the research and clinical markets. However, challenges include high R&D investment to maintain technological leadership, pricing pressures from budget-conscious institutions, and vulnerability to fluctuations in research funding cycles. Looking ahead, this subsector stands to benefit from tailwinds such as growing demand for tools supporting emerging fields like synthetic biology and personalized medicine. There is also a rise in automation and AI-driven solutions in laboratories that could create new opportunities to sell tools and consumables. Nevertheless, headwinds exist. These companies tend to be at the mercy of supply chain disruptions and sensitivity to macroeconomic conditions that impact funding for research initiatives. The 10 research tools & consumables stocks we track reported a mixed Q1. As a group, revenues beat analysts' consensus estimates by 1.5% while next quarter's revenue guidance was 0.6% above. While some research tools & consumables stocks have fared somewhat better than others, they have collectively declined. On average, share prices are down 1.3% since the latest earnings results. With over 14,000 sales personnel and a portfolio spanning more than 2,500 technology manufacturers, Thermo Fisher Scientific (NYSE:TMO) provides scientific equipment, reagents, consumables, software, and laboratory services to pharmaceutical, biotech, academic, and healthcare customers worldwide. Thermo Fisher reported revenues of $10.36 billion, flat year on year. This print exceeded analysts' expectations by 1.3%. Despite the top-line beat, it was still a mixed quarter for the company with a narrow beat of analysts' organic revenue estimates but a slight miss of analysts' operating income estimates. 'We delivered very strong performance in the first quarter in a more uncertain macroeconomic environment, and I'm incredibly proud of our team's execution,' said Marc N. Casper, chairman, president, and chief executive officer of Thermo Fisher Scientific. The stock is down 7.8% since reporting and currently trades at $400.50. Is now the time to buy Thermo Fisher? Access our full analysis of the earnings results here, it's free. Born from a real estate investment trust that transformed into a manufacturing powerhouse, Danaher (NYSE:DHR) is a global science and technology company that provides specialized equipment, software, and services for biotechnology, life sciences, and diagnostics. Danaher reported revenues of $5.74 billion, flat year on year, outperforming analysts' expectations by 2.7%. The business had a very strong quarter with an impressive beat of analysts' organic revenue and EPS estimates. The market seems content with the results as the stock is up 3.1% since reporting. It currently trades at $190.50. Is now the time to buy Danaher? Access our full analysis of the earnings results here, it's free. With roots dating back to 1904 and embedded in virtually every stage of scientific research and production, Avantor (NYSE:AVTR) provides mission-critical products, materials, and services to customers in biopharma, healthcare, education, and advanced technology industries. Avantor reported revenues of $1.58 billion, down 5.9% year on year, falling short of analysts' expectations by 1.6%. It was a softer quarter as it posted a miss of analysts' organic revenue and EPS estimates. Avantor delivered the weakest performance against analyst estimates and slowest revenue growth in the group. As expected, the stock is down 16.5% since the results and currently trades at $12.91. Read our full analysis of Avantor's results here. With a critical role in ensuring the safety of millions of patients worldwide, Sotera Health (NASDAQGS:SHC) provides sterilization services, lab testing, and advisory services to ensure medical devices, pharmaceuticals, and food products are safe for use. Sotera Health Company reported revenues of $254.5 million, up 2.6% year on year. This number topped analysts' expectations by 3.1%. Overall, it was a strong quarter as it also logged a solid beat of analysts' organic revenue and EPS estimates. The stock is up 6.5% since reporting and currently trades at $12.24. Read our full, actionable report on Sotera Health Company here, it's free. With roots dating back to the pioneering days of nuclear magnetic resonance technology, Bruker (NASDAQ:BRKR) develops and manufactures high-performance scientific instruments that enable researchers and industrial analysts to explore materials at microscopic, molecular, and cellular levels. Bruker reported revenues of $801.4 million, up 11% year on year. This print surpassed analysts' expectations by 4.3%. Aside from that, it was a satisfactory quarter as it also produced a solid beat of analysts' organic revenue estimates but a significant miss of analysts' full-year EPS guidance estimates. Bruker scored the biggest analyst estimates beat, fastest revenue growth, and highest full-year guidance raise among its peers. The stock is down 8.2% since reporting and currently trades at $36.21. Read our full, actionable report on Bruker here, it's free. As a result of the Fed's rate hikes in 2022 and 2023, inflation has come down from frothy levels post-pandemic. The general rise in the price of goods and services is trending towards the Fed's 2% goal as of late, which is good news. The higher rates that fought inflation also didn't slow economic activity enough to catalyze a recession. So far, soft landing. This, combined with recent rate cuts (half a percent in September 2024 and a quarter percent in November 2024) have led to strong stock market performance in 2024. The icing on the cake for 2024 returns was Donald Trump's victory in the U.S. Presidential Election in early November, sending major indices to all-time highs in the week following the election. Still, debates around the health of the economy and the impact of potential tariffs and corporate tax cuts remain, leaving much uncertainty around 2025. Want to invest in winners with rock-solid fundamentals? Check out our 9 Best Market-Beating Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.
